ABCL
Abcellera Biologics Inc
13.70$
-1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.6% | -213.7% | -419.0% | -402.3% | -445.6% | -158.4% | -272.8% | -189.7% | -587.3% | -77.5% | -403.2% | -836.1% | -233.8% | |
| 112.3% | 99.2% | 68.0% | 519.4% | 588.5% | -358.4% | 156.0% | 41.3% | 80.8% | 20.0% | 104.1% | 127.7% | 45.4% | |
| 240.4% | 179.2% | 174.9% | 242.8% | 263.8% | 301.5% | 349.1% | 83.2% | 155.2% | 28.8% | 144.5% | 303.4% | 77.2% | |
| 211.2% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 108.5% | 15.4% | -271.0% | -106.3% | -89.4% | -315.1% | 247.1% | -98.3% | -202.5% | -102.5% | -161.2% | -79.5% | -122.0% | |
| 308.1% | 157.2% | 242.5% | 270.3% | 285.6% | 309.5% | 251.1% | 78.2% | 99.7% | 21.9% | 46.1% | 52.6% | 37.4% | |
| -193.8% | -265.0% | 300.5% | 703.5% | 60.6% | 707.0% | 187.4% | -186.2% | 407.5% | 167.5% | -301.6% | 280.0% | 147.9% | |
| – | – | – | – | – | -31.3% | – | – | – | – | – | – | – | |
| 106.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 100.5% | 41.0% | 28.4% | 35.7% | 48.4% | 82.0% | 141.0% | -19.8% | 82.3% | 9.2% | 86.5% | 335.4% | 48.8% | |
| -111.0% | -426.0% | -97.9% | 337.8% | -333.1% | 587.8% | 69.4% | -391.2% | -103.6% | 99.9% | -636.8% | -194.2% | -38.2% | |
| -309.7% | -370.9% | -661.5% | -672.6% | -731.2% | -467.9% | -524.0% | -267.9% | -687.0% | -99.4% | -449.2% | -888.8% | -271.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.